Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Juno closes $134mm Series B round

Executive Summary

Juno Therapeutics Inc. (cancer immunotherapies) closed its second huge financing in less than 12 months. The company raised $134mm through its Series B round from all existing major investors (Arch Venture Partners and Crestline Investors were key Series A participants) as well as ten public mutual funds and health care-focused funds. Juno's Series A round closed in April bringing in a whopping $176mm; proceeds from both financings are funding Juno's pipeline of chimeric antigen receptor and T-cell receptor therapies.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies